The use of atorvastatin treatment in usual care environments: Pooled analysis of six prospective, observational studies in 90,535 patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 8, 2004, Pages 423-433

  Vetter, Silke ^a   Ruf, G ^a   Regourd, E ^a   Marz W ^b  

^a PFIZER INC   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Atorvastatin; Cholesterol; Clinical practice; Guidelines; Lipid lowering therapy; Meta analysis; Observational study; Triglycerides

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VASODILATOR AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; GERMANY; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTPATIENT; PHASE 4 CLINICAL TRIAL; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RHABDOMYOLYSIS; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 4444373923     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp42423     Document Type: Article

References (28)

1. American Diabetes Association 2000 Management of dyslipidemia in adults with diabetes. Diabetes Care 23 (Suppl 1). S57-60
2. American Diabetes Association 2002 Management of dyslipidemia in adults with diabetes. Diabetes Care 25 (Suppl 1): S74-77
3. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH 2001 Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 111: 185-191
4. Athyros VG, Papageorgiou AA, Mercouris BR et al 2002 Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18: 220-228
5. Bernini F, Poli A, Paoletti R 2001 Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovascular Drug Therapy 15: 211-218
6. Cannon CP, Braunwald E, McCabe CH et al 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504
7. EUROASPIRE II Study Group 2001 Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22: 554-572
8. EUROASPIRE I and II Group 2001 Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357: 995-1001
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) 2001 JAMA 285: 2486-2497
10. Feely J 1999 The therapeutic gap: compliance with medication and guidelines. Atherosclerosis 147 (Suppl 1): S31-37
11. Frolkis JP, Pearce GL, Nambi V et al 2002 Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 113: 625-629
12. Grol R, Grimshaw J 2003 From best evidence to best practice: effective implementation of change in patients' care. Lancet 362: 1225-1230
13. Hilleman DE, Wurdeman RL, Lenz TL 2001 Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 21. 410-415
14. Law MR, Wald NJ, Rudnicka AR 2003 Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423-1450
15. März W, Wollschläger H, Klein G et al 1999 Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease oopulation (the TARGET TANGIBLE trial). Am J Cardiol 84: 7-13
16. Mc Pherson R, Angus C, Murray P, Genest J 2001 Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). Am Heart J. 141: 949-956
17. Newman CB, Palmer G, Silbershatz H, Szarek M 2003 Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92: 670-676
18. Pearson TA, Laurora I, Chu H, Kafonek S 2000 The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160: 459-467
19. Ruof J, Klein G, März W et al 2002 Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 35: 48-53
20. Schwartz GG, Olsson AG, Ezekowitz MD et al 2001 Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 285: 1711-1718
21. Second Joint Task Force of European and other Societies on Coronary Prevention 1998 Prevention of coronary heart disease in clinical practice: recommendations of' the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19. 1434-1503
22. Sever PS, Dahlöf B, Poulter NR et al 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158
23. Smilde TJ, Van Wissen S, Wollersheim H et al 2001 Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357: 577-581
24. Stein EA 2002 Management of dyslipidemia in the high-risk patient. Am Heart J 144: S43-50
25. Tu K, Mandani MM, Tu JV 2002 Hypertension guidelines in elderly patients: is anybody listening? Am J Med 113: 52-58
26. Vicari RM, Wan GJ, Aura AM et al 2000 Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. Arch Fam Med 9: 898-905
27. Waters D 2003 Statins and safety: applying the results of randomized trials to clinical practice. Am J Cardiol 92: 692-695
28. Wierzbicki AS 2001 Atorvastatin. Expert Opin Pharmacother 2: 819-830